LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・United Therapeutics Corp

Search

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

540.4 -1.75

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

536.2

Max

556.82

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M 275M
Pardavimai	-8.7M 782M
P/E Sektoriaus vid.	20.136 49.052
Pelnas, tenkantis vienai akcijai	5.82
Pelno marža	35.176
Darbuotojai	1,400
EBITDA	-176M 348M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+20.39% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.5B 23B
Ankstesnė atidarymo kaina	542.15
Ankstesnė uždarymo kaina	540.4

Naujienos nuotaikos

By Acuity

18%

82%

34 / 344 reitingas Healthcare

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-10 23:36; UTC

Uždarbis

Correction to Oracle Reports Higher 4Q Profit Article

2026-06-10 23:19; UTC

Karštos akcijos

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026-06-10 23:09; UTC

Pagrindinės rinkos jėgos

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026-06-10 23:04; UTC

Uždarbis

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026-06-10 20:44; UTC

Pagrindinės rinkos jėgos

Caterpillar Raises Quarterly Dividend 8%

2026-06-10 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Should Take No Options Off The Table

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026-06-10 23:47; UTC

Rinkos pokalbiai

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026-06-10 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026-06-10 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026-06-10 23:32; UTC

Rinkos pokalbiai

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026-06-10 23:20; UTC

Rinkos pokalbiai

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026-06-10 22:05; UTC

Rinkos pokalbiai

Correction to Bank of Canada Stays on Hold Market Talk

2026-06-10 21:57; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:52; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:35; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:22; UTC

Uždarbis

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026-06-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-10 20:39; UTC

Rinkos pokalbiai

Uždarbis

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026-06-10 20:34; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 20:33; UTC

Uždarbis

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

20.39% į viršų

12 mėnesių prognozė

Vidutinis 665.9 USD 20.39%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

8

Pirkti

2

Laikyti

0

Parduoti

Remiantis 10 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

34 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat